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Die Mischung machtޑs: Die Carboxyamido-Einheit ist wichtig für 
die biologische Aktivität der Tetracycline. Biosynthesegene 
(OxyD, OxyP) der Oxytetracyclin(OTC)-Polyketid-Synthase (PKS) 
aus Streptomyces rimosus wurden gezielt in Amycolatopsis 
sulphurea, dem Produzenten des untypischen Tetracyclins 
Chelocardin (CHD) exprimiert. Das entsprechende Analogon 
CDCHD, das mit hoher Ausbeute produziert wurde, hat eine stark 
verbesserte antibakterielle Aktivität. 
Kombinatorische Biosynthese 
Antibiotika 
Biosynthesen 
Chelocardin 
Polyketide 
Tetracycline 
Mix and match: The carboxyamido moiety of tetracyclines is 
important for their bioactivity. Through rational biosynthetic 
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engineering, biosynthesis genes (OxyD, OxyP) from the 
oxytetracycline (OTC) polyketide synthase (PKS) from 
Streptomyces rimosus were expressed in Amycolatopsis 
sulphurea, a producer of the atypical tetracycline chelocardin 
(CHD). The resulting CHD analogue (CDCHD) was produced at high 
yield and exibits greatly improved antibacterial activity.  
 
Combinatorial Biosynthesis 
antibiotics 
biosynthesis 
chelocardin 
polyketides 
tetracyclines 
Antimicrobial resistance and the shortage of novel antibiotics 
have led to an urgent need for new antibacterial drug leads. 
Several existing natural product scaffolds (including 
chelocardins) have not been developed because their suboptimal 
pharmacological properties could not be addressed at the time. 
It is demonstrated here that reviving such compounds through 
the application of biosynthetic engineering can deliver novel 
drug candidates. Through a rational approach, the carboxyamido 
moiety of tetracyclines (an important structural feature for 
their bioactivity) was introduced into the chelocardins, which 
are atypical tetracyclines with an unknown mode of action. A 
broad-spectrum antibiotic lead was generated with 
significantly improved activity, including against all Gram-
negative pathogens of the ESKAPE panel. Since the lead 
structure is also amenable to further chemical modification, 
it is a platform for further development through medicinal 
chemistry and genetic engineering. 
The evolution of multidrug-resistant pathogens presents 
one of the greatest challenges to modern health care. There is 
a critical shortage of effective antibiotics, particularly 
against Gram-negative pathogens belonging to the ESKAPE group 
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(see Table^^1<tabr1>), including Pseudomonas aeruginosa, which 
is an important pathogen that causes hospital-acquired 
infections.[1] Consequently, new antibiotics from novel 
antibiotic classes that bypass current resistance mechanisms, 
and preferably with a new mode of action,[2] need to be 
translated rapidly into the clinic. Approaches such as 
screening natural product libraries and developing chemically 
synthesised antibiotics based on novel targets have shown that 
the identification of promising anti-infective lead structures 
is a rare event.[3] 
Based on more than 70^^years of antibacterial drug 
development, an attractive alternative is to reassess 
unexploited and underutilised structural scaffolds of proven 
antibacterial potency and resistance-breaking properties, and 
to develop these further by using cutting-edge synthetic 
biology. 
Antibiotics such as tetracyclines (TCs), which were 
formerly highly-effective against both Gram-positive and Gram-
negative pathogens, are now ineffective owing to widespread 
antibiotic resistance.[4] TCs are bacteriostatic; the first 
major class of therapeutics to be termed broad-spectrum 
antibiotic.[5] Clinically-important TCs, such as doxycycline, 
minocycline, and glycylcyclines (a new class of TCs), are 
termed typical TCs. Their mode of action involves binding to 
the ribosome during polypeptide elongation to inhibit 
translation.[6] Chelocardin (CHD, 3; Figure^^1^b<figr1>), which 
is produced by Amycolatopsis sulphurea,[7] is regarded as a 
structurally atypical TC and shows bactericidal activity.[8] 
Initial data on the mode of action of CHD exist, but the exact 
mechanism of action has yet to be elucidated.[8,^9] CHD is 
effective against many multidrug-resistant pathogens, 
including some difficult-to-treat Gram-negative bacteria. 
Importantly, it is also effective against TC-resistant 
strains, except for Pseudomonas aeruginosa 
(Table^^1<xtabr1>).[10] No toxicity from CHD was observed 
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following oral administration in rats or dogs.[11] In a small 
Phase^^II clinical study in the late 1970s, twelve patients 
receiving CHD orally were cured of urinary-tract infections 
(pyelonephritis).[11] Only one minor gastrointestinal adverse 
event was reported, while three patients were cleared of 
tetracycline-resistant infections, thus showing the potential 
of CHD to combat difficult infections. Nevertheless, CHD was 
not developed further as an antibiotic. 
We re-examined CHD activity with a panel of multidrug-
resistant clinical isolates (Table^^1<xtabr1>) and the results 
confirm its reported potency.[10] Although CHD has the typical 
four-ring TC backbone, it also has several unique structural 
features that are believed to contribute to a mode of action 
most likely different to that of other TCs. Compared to 
clinically used TCs these features include: an alternative 
aromatization pattern at rings^^D and C; functionalization of 
CHD at C9; and opposite sterochemistry of the non-methylated 
amino group at C4 (Figure^^1<xfigr1>).<?><?>Sentence ok?<?><?> 
Furthermore, whereas typical TCs bind to the ribosome in a 
cleft into which TCs fit owing to a kink between rings^^A and 
B,[12] CHD is a more planar molecule and consequently may not 
bind to the ribosome. No cross-resistance is known. One 
important feature of all medically-important TCs is the 
carboxyamido moiety at C2 (1, Figure^^1<xfigr1>). In contrast, 
CHD carries an acetyl group at C2 (3, Figure^^1<xfigr1>). 
Biosynthetically, this difference is due to priming by acetate 
instead of malonamate during initiation 
(Figure^^2^b<figr2>).[13] Although the exact mechanism of 
initiation in oxytetracycline (OTC) biosynthesis is still not 
well understood, it is carried out by a minimal polyketide 
synthase (PKS)<?><?>ok?<?><?> OxyABC, consisting of two 
ketosynthase units KSĮ and KSȕ, and an acyl-carrier protein 
(ACP), an amidotransferase (AMT) OxyD, which catalyzes the 
transamination reaction of malonate to malonamate 
(Figure^^2<xfigr2>), and an acyltransferases (AT) homologue, 
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OxyP.[13] The function of the AT domain in OTC biosynthesis is 
not yet clearly defined. Interestingly, inactivation of oxyP 
did not abolish the biosynthesis of OTC but did increase the 
proportion of 2-acetyl-2-decarboxyamido-oxytetracycline (2, 
ADOTC) compared to OTC (1; Figure^^1<xfigr1>).[13] Moreover, the 
carboxyamido moiety in OTC is crucial for the antibacterial 
activity of typical TCs.[14] Recently, we reported the cloning 
of the gene cluster for CHD biosynthesis, which enabled the 
production of CHD analogues by using biosynthetic 
engineering.[15] Since CHD is exclusively acetate-primed 
(Figure^^2^b<xfigr2>), the CHD biosynthetic cluster, as 
expected, contained no AT or AMT homologue.[15] We thus 
attempted to prime CHD biosynthesis with the carboxyamido 
moiety. Aiming to produce an amidated analogue of CHD, 
specifically 2-carboxyamido-2-deacetyl-chelocardin (CDCHD, 4; 
Figure^^1^b<xfigr1>), oxyD and oxyP from the S. rimosus otc 
gene cluster[16] were introduced into A. sulphurea individually 
and in combination by using three integrative plasmids: 
pAB03oxyD, pAB03oxyP and pAB03oxyDP (Figure^^S1 in the 
Supporting Information). The resulting A. sulphurea 
transformants were analyzed for production of CHD and CDCHD by 
HPLC (Figure^^S2a) and LC--MS (Figure^^S3). Remarkably, in the 
genetically engineered PKS system of chd in A. sulphurea, 
efficient malonamate priming is indeed possible but, 
interestingly, it is dependent on both oxyP and oxyD. This is 
in contrast to OTC biosynthesis in S. rimosus, where oxyP is 
practically dispensable. Biosynthesis of the malonamate-primed 
CDCHD was efficient, reaching a yield of around 80^% of the 
total CHD produced by this strain (Figure^^S2). The structure 
of CDCHD, particularly the presence of the carboxyamido 
moiety, was confirmed by LC--MS, HRMS, and 2D NMR spectroscopy 
(Figure^^3<figr3> for the most important NMR correlations, 
also see the Supporting information). Incomplete conversion of 
CHD into CDCHD could be due to insufficient supply/processing 
of the putative starter unit, malonamyl-CoA, or competition by 
acetate starter units through direct transfer to the KSĮ. 
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Engineered enzymes often produce the desired product at 
significantly lower yield, thus seriously hampering downstream 
development.[17] Remarkably, however, the highest yield of CDCHD 
in the recombinant strain containing pAB03oxyDP was around 
400^^mg^L<M->1 (Figure^^S2b), compared to a yield of 900^^mg^L<M-
>1 CHD achieved when using the wild-type A. sulphurea strain 
containing an empty plasmid. 
Next, we isolated CDCHD and undertook comparative 
in^^vitro testing of CHD and CDCHD against a collection of 
well-characterised multidrug-resistant clinical isolates 
(Table^^1<xtabr1> and the Supporting Information). Remarkably, 
the in^^vitro activity of CDCHD against these isolates was 
usually 2--4 times higher than that of CHD, thus confirming 
the importance of the 2-carboxyamido moiety for activity. For 
multidrug-resistant enterobacteria, methicillin-resistant 
Staphylocccus aureus, and glycopeptide-resistant Enterococcus 
faecium, CDCHD showed in^^vitro activity superior to that of 
CHD, with corresponding MIC90 and MIC50 values differing 2- to 
4-fold. CDCHD showed a remarkable improvement compared to CHD 
against Klebsiella pneumoniae, which was inhibited at 
16AAȝJ^mL<M->1 or less by CHD and gave MIC90 and MIC50 values for 
CDCHD below 4AAȝJ^mL<M->1. CHD was only slightly less active 
compared to CDCHD against A. baumannii and almost inactive 
against P. aeruginosa (for which the MIC90 value was 
>64AAȝJ^mL<M->1; Table^^1<xtabr1>). Importantly, CDCHD showed 
much higher in^^vitro activity against P. aeruginosa compared 
to CHD: 13 out of 15 multidrug-resistant isolates were 
inhibited at 16AAȝJ^mL<M->1 or lower. However, the MIC50 
(8AAȝJ^mL<M->1) and MIC90 (32AAȝJ^mL<M->1) values for CDCHD against 
P. aeruginosa were still 8- to 16-times higher than with S. 
aureus or E. faecium (2--4AAȝJ^mL<M->1). Relatively high MIC 
values against A. baumannii and P. aeruginosa and some 
multidrug-resistant K. pneumoniae species may indicate the 
involvement of intrinsic resistance mechanisms (e.g., efflux 
pumps). Additional studies to define the mechanisms of 
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resistance to CHD and CDCHD are currently ongoing in our 
laboratories in order to understand the bacterial strategies 
used to escape their effects. 
Although the enzymatic mechanisms leading to carboxyamido 
moiety formation in TCs is of medicinal interest,[16,^18] our 
study is, to the best of our knowledge, the first successful 
heterologous expression of the AT and AMT from the otc cluster 
to derive a novel malonamate-primed molecule. The addition of 
this carboxyamido moiety significantly increases the 
biological activity of CHD. The acetate-primed impurity of 
OTC, ADOTC (2), also shows a tenfold reduction in 
antibacterial activity.[19]Our findings for CHD are thus in 
agreement with the structure--activity relationships (SAR) 
found in typical TC antibiotics.[14] 
Our current understanding of the priming reactions in 
type^^II PKSs, which mostly involve minimal PKS ketosynthase 
complexes[13,^20] and an additional auxiliary acyltransferase 
(AT), is still limited, particularly when considering applying 
combinatorial approaches to generate potentially useful 
compounds.Reconstitution of the OTC minimal PKS in a 
heterologous host resulted in the biosynthesis of a truncated 
polyketide initiated with acetate. The addition of oxyD alone 
to this artificial system was sufficient to produce the 
amidated derivative as the major product.[16] Thus suggesting 
that rather than being an acyltransferase, OxyP is a thiolase 
that suppresses priming by acetate by removing the competing 
acetyl units, as similarly observed in other type^^II PKS 
systems.[21]However, in contrast to the priming steps in OTC 
biosynthesis,[13] where the AMT oxyD alone is sufficient for the 
efficient production of OTC, when only oxyD was expressed in 
A. sulphurea, amidated CDCHD was biosynthesised in very low 
yield (Figure^^S2). The involvement of OxyP thus has much 
greater importance in the priming of CDCHD. 
Most of the semisynthetic TCs used in the clinic, or 
currently in clinical development, derive from 6-
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demethyltetracyclines (6-DMTCs).[22] New approaches for total 
synthesis routes were recently reported to further expand the 
chemical diversity of the TC scaffold.[23] Powerful biosynthetic 
engineering routes for the development of TC analogues have 
also been reported.[24] Our current report of the incorporation 
of the carboxyamido moiety into chelocardins provides a unique 
diversification of the TC backbone and the resulting 
derivative shows potent antibacterial activity and could prove 
to be a promising drug lead. 
Overall we have demonstrated efficient incorporation of 
the carboxyamido starter moiety, which is known to be 
important for tetracycline activity, into CHD. A high yield of 
this novel compound (CDCHD) was obtained, and the process 
should be directly transferable to an industrial scale. 
Therefore, we not only demonstrated the utility of this 
biosynthetic engineering approach but also developed a unique 
tetracycline lead with potent antibacterial activity. This 
compound class can now be diversified further by semisynthesis 
or further biosynthetic engineering in the context of wider 
medicinal chemistry approaches to develop urgently needed 
novel broad-spectrum antibacterial drugs. 
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Figure^^1 Structures of oxytetracycline (OTC, 1), 2-acetyl-2-
decarboxyamido-oxytetracycline (ADOTC, 2), chelocardin (CHD, 
3), and 2-carboxyamido-2-deacetyl-chelocardin (CDCHD, 4). 
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Figure^^2 Priming steps in OTC biosynthesis (a)[13] and CHD 
biosynthesis (b),[15] and proposed malonamate priming in CDCHD 
biosythesis (c). The starter unit in OTC biosynthesis is 
indicated in red, the CHD structure in blue, and OTC in black. 
 
Figure^^3 Significant HMBC and COSY correlations of CDCHD. 
 
Table^^1 CHD and CDCHD activities against clinical 
isolates.<W=3> 
   
Number of isolates inhibited by the indicated 
concentration^^[ȝJ^mL<M->1] 
Species N Drug 
0.12
5 
0.2
5 
0.
5 
1 2 4 8 
1
6 
3
2 
6
4 
>6
4 
MIC50
[a] MIC90
[a] 
E. 
faecium 
10 
CHD     2 5 3     <dp>4 <dp>8 
CDCH
D 
    4 6      <dp>2 <dp>2 
 14 
S. aureus 
MR 
20 
CHD   1 3 5 
1
0 
1     <dp>4 <dp>4 
CDCH
D 
  1 1 
1
0 
8      <dp>2 <dp>4 
K. 
pneumonia
e 
25 
CHD   2 5 8 4 3 3    <dp>2 1<dp>6 
CDCH
D 
1 2 4 7 7 4      <dp>1 <dp>4 
A. 
baumannii 
20 
CHD     2 5 8 4 1   <dp>8 1<dp>6 
CDCH
D 
     2 
1
2 
5 1   <dp>8 1<dp>6 
P. 
aeruginos
a 
15 
CHD         1 8 6 6<dp>4 >6<dp>4 
CDCH
D 
      8 5 2   <dp>8 3<dp>2 
E. 
cloacae 
20 
CHD    1 
1
2 
5 2     <dp>2 <dp>4 
CDCH
D 
  2 
1
1 
7       <dp>1 <dp>2 
E. coli 15 
CHD   3 4 4 2 1 1    <dp>2 <dp>8 
CDCH
D 
 2 6 3 3 1      <dp>0.5 <dp>2 
All 
organisms 
12
5 
CHD   6 
1
3 
3
3 
3
1 
1
8 
8 2 8 6 <dp>4 1<dp>6 
CDCH
D 
1 4 13 
2
2 
3
1 
2
1 
2
0 
1
0 
3   <dp>2 <dp>8 
[a]^^MIC=minimal inhibitory concentration. 
